Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 1, 2013, Pages 64-71

  Feng, Felix Y ^a,b   Blas, Kevin ^a   Olson, Karin ^a   Stenmark, Matthew ^a   Sandler, Howard ^c   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CUMULATIVE INCIDENCE; HIGH-RISK PROSTATE CANCERS; LONG-TERM ANDROGEN DEPRIVATION; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; RETROSPECTIVE ANALYSIS; RETROSPECTIVE EVALUATIONS;

MULTIVARIANT ANALYSIS; PATHOLOGY; PATIENT MONITORING; PESTICIDE EFFECTS; RADIOTHERAPY;

DISEASES;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE ESCALATION; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876122045     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.11.024     Document Type: Article

References (22)

1. A. Dal Pra, F.L. Cury, and L. Souhami Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review Curr Oncol 17 2010 28 38
2. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
3. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
4. P.R. Warde, M.D. Mason, and M.R. Sydes Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633) J Clin Oncol 28 2010 abstr CRA4504
5. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
6. P. Diez, I.S. Vogelius, and S.M. Bentzen A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer Int J Radiat Oncol Biol Phys 77 2010 1066 1071
7. D.A. Kuban, L.B. Levy, and M.R. Cheung Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease? Int J Radiat Oncol Biol Phys 79 2011 1310 1317
8. A. Zapatero, F. Garcia-Vicente, and C. Martin de Vidales Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 81 2011 1279 1285
9. D. Krauss, L. Kestin, and H. Ye Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1064 1071
10. S.L. Liauw, W.M. Stadler, and D. Correa Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy Int J Radiat Oncol Biol Phys 77 2010 125 130
11. S. Williams, M. Buyyounouski, and L. Kestin Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose Int J Radiat Oncol Biol Phys 79 2011 724 731
12. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. M.R. Cooperberg, D.J. Pasta, and E.P. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942 (Pubitemid 40675216)
14. M.W. Kattan, M.J. Zelefsky, and P.A. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
15. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
16. R. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1143
17. M.C. Abramowitz, T. Li, and M.K. Buyyounouski The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Cancer 112 2008 55 60
18. W. Kwan, T. Pickles, and G. Duncan PSA failure and the risk of death in prostate cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 60 2004 1040 1046 (Pubitemid 39440787)
19. D.A. Hamstra, K. Bae, and M.V. Pilepich Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials Int J Radiat Oncol Biol Phys 81 2011 1293 1301
20. P.J. Saylor, and M.R. Smith Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer J Natl Compr Canc Netw 8 2010 211 223
21. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
22. P.L. Nguyen, Y. Je, and F.A. Schutz Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366